Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/127596
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | González Barca, Eva | - |
dc.contributor.author | Domingo Domènech, Eva | - |
dc.contributor.author | Capote, Francisco Javier | - |
dc.contributor.author | Gómez Codina, Jose | - |
dc.contributor.author | Salar, Antonio | - |
dc.contributor.author | Bailen, Alicia | - |
dc.contributor.author | Ribera, Josep Maria | - |
dc.contributor.author | López, Andres | - |
dc.contributor.author | Briones, Javier | - |
dc.contributor.author | Muñoz, Andres | - |
dc.contributor.author | Encuentra, Maite | - |
dc.contributor.author | Fernández de Sevilla Ribosa, Alberto | - |
dc.contributor.author | GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) | - |
dc.contributor.author | GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear) | - |
dc.contributor.author | GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas) | - |
dc.date.accessioned | 2019-01-25T08:51:06Z | - |
dc.date.available | 2019-01-25T08:51:06Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0390-6078 | - |
dc.identifier.uri | http://hdl.handle.net/2445/127596 | - |
dc.description.abstract | Background and Objectives The elective treatment of patients with post-transplant lymphoproliferative disorders is controversial. The purpose of this trial was to evaluate the efficacy of treatment with extended doses of rituximab adapted to the response in patients with post-transplant lymphoproliferative disorders after solid organ transplantation. Design and Methods This was a prospective, multicenter, phase 11 trial. Patients were treated with reduction of immunosuppression and four weekly infusions of rituximab. Those patients who did not achieve complete remission (CR) received a second course of four rituximab infusions. The primary end-point of the study was the CR rate. Results Thirty-eight patients were assesable. One episode of grade 4 neutropenia was the only severe adverse event observed. After the first course of rituximab, 13 (34.2%) patients achieved CR, 8 patients did not respond, and 17 patients achieved partial remission. Among those 17 patients, 12 could be treated with a second course of rituximab, and 10 (83.3%) achieved CR, yielding an intention-to-treat CR rate of 60.5%. Eight patients excluded from the trial because of absence of CR were treated with rituximab combined with chemotherapy, and six (75%) achieved CR. Event-free survival was 42% and overall survival was 47% at 27.5 months. Fourteen patients died, ten of progression of their post-transplant lymphoproliferative disorder. Interpretation and Conclusions These results confirm that extended treatment with rituximab can obtain a high rate of CR in patients with post-transplant lymphoproliferative disorders after solid organ transplantation without increasing toxicity, and should be recommended as initial therapy for these patients. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Ferrata Storti Foundation | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3324/haematol.11360 | - |
dc.relation.ispartof | Haematologica, 2007, vol. 92, num. 11, p. 1489-1494 | - |
dc.relation.uri | https://doi.org/10.3324/haematol.11360 | - |
dc.rights | cc-by-nc (c) Ferrata Storti Foundation, 2007 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Malalties hematològiques | - |
dc.subject.classification | Pronòstic mèdic | - |
dc.subject.classification | Terapèutica | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Hematologic diseases | - |
dc.subject.other | Prognosis | - |
dc.subject.other | Therapeutics | - |
dc.title | Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 557804 | - |
dc.date.updated | 2019-01-25T08:51:06Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
557804.pdf | 178.08 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License